Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Internal Medicine | Neurology | Pharmacy | Psychiatry | Journal

Back to Journal Articles

Antidepressants Don’t Impact Stimulants’ Efficacy in ADHD

Last Updated: August 16, 2011.

 

Concomitant use of antidepressants doesn't affect osmotic release oral system methylphenidate

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In adults with attention deficit hyperactivity disorder, concomitant use of antidepressants does not affect the safety or efficacy of osmotic release oral system methylphenidate, according to a study published online Aug. 5 in CNS Neuroscience & Therapeutics.

TUESDAY, Aug. 16 (HealthDay News) -- In adults with attention deficit hyperactivity disorder (ADHD), concomitant use of antidepressants does not affect the safety or efficacy of osmotic release oral system methylphenidate (OROS-MPH), according to a study published online Aug. 5 in CNS Neuroscience & Therapeutics.

Joseph Biederman, M.D., from Massachusetts General Hospital in Boston, and colleagues examined whether the response to OROS-MPH was moderated by the concomitant use of antidepressants in adults with ADHD. A total of 223 patients with anxiety disorders and depression were analyzed, including 109 in the OROS-MPH group and 114 in the placebo group. Patients treated with a stable medication regimen of non-monoamine oxidase inhibitor antidepressants or benzodiazepines for at least three months were enrolled. Patients were required to have Hamilton-Depression and Hamilton-Anxiety scales below 15 (mild range) at the time they were enrolled.

The investigators found no association between concomitant antidepressant use at baseline and ADHD response, OROS-MPH dose, study completion rate, adverse effects, or worsening of anxiety or depression. There was nominally significant evidence of a lifetime history of mood or anxiety disorders being a moderator of ADHD symptoms. A potential moderator of dose at end point was a lifetime history of substance use disorder.

"We found few moderating effects in this large clinical trial of OROS-MPH in adults with ADHD, which supports the robustness of the clinical response to OROS-MPH in adult ADHD despite variable clinical pictures," the authors write.

All of the study authors disclosed financial relationships with the pharmaceutical and health care industry, including Ortho-McNeil Janssen Scientific Affairs, which provided financial support for the study.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: Diabetes, Islet Autoantibodies Localize to Same HLA Region Next: Patient Care Improves With Anticoagulation Service

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.